

The family of secreted phospholipases A₂: from toxic to therapeutic enzymes.



Gérard LAMBEAU

Institute of Molecular and Cellular Pharmacology, CNRS and
University of Nice Sophia Antipolis, Valbonne, FRANCE.

Secreted phospholipases A₂ (sPLA₂s) are low molecular mass, Ca²⁺-requiring enzymes with a His-Asp catalytic dyad. These enzymes were first discovered in animal venoms where they usually exert digestive and toxic functions towards preys. Over the years, 10 different mammalian sPLA₂ isoforms homologous to the venom sPLA₂s have been cloned. These enzymes exhibit unique tissue and cellular localizations and enzymatic properties, suggesting distinct biological roles. They also bind to specific proteins including PLA₂R1, a C-type lectin receptor.

It is now clear that mammalian sPLA₂s are involved in diverse biological events through enzymatic-dependent and -independent processes, act redundantly or non-redundantly in pathophysiology, and may represent potential drug targets or bioactive drugs in several diseases. Over the years, several sPLA₂ inhibitors have been developed by pharmaceutical companies and clinically tested, but none of them are currently used in the clinic. In this talk, I will present novel biological roles of sPLA₂s and PLA₂R1 in atherosclerosis, host defense, fertility, cancer and membranous nephropathy, a human auto-immune kidney disease.